Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2011

Novartis Discontinues a Phase III Study in Gastrointestinal Stromal Tumors

  • Novartis is discontinuing the Phase III Enestg1 study evaluating Tasigna® (nilotinib) as first-line therapy for gastrointestinal stromal tumors (GIST). The study’s independent data monitoring committee said interim data from the trial suggest it is unlikely to demonstrate any benefits of Tasigna over Glivec® (imatinib) in terms of improving progression-free survival. The Enestg1 trial was initiated in 2009, and aimed to enroll over 700 GIST patients newly diagnosed with unresectable and/or metastatic GIST.

    Tasigna is already approved in major markets including the EU, U.S,. and Japan, for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

    The drug has also been approved in over 90 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients who are resistant or intolerant to at least one prior therapy, including Glivec.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »